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randomized to either an early or late invasive strategy.
Total
Early
treatment
(n[71)
Late
treatment
(n[58) p-value RR (95% CI)
30 d follow-up
Combined incidence of
death, re-
infarction or
recurrent
ischemia (PEP)
8.9% 5.8% 12.7% .213 0.46 (0.14-1.48)
death 0% 0% 0% NA
MI 0% 0% 0% NA
recurrent ischemia 8.9% 5.8% 12.7% .213 0.46 (0.14-1.48)
Enzymatic infarct size
(single cardiac
TropT) ug/l med
(IQR)
0.27 (0.11-0.86) 0.27 (0.07-0.55) 0.27 (0.12-1.12) .100
bleeding 22.6% 26.1% 18.2% .296 1.44 (0.72-2.85)
major bleeding 12.1% 15.9% 7.3% .141 2.19 (0.74-6.51)
2 y follow-up
combined incidence of
death, re-
infarction or
recurrent
20.3% 18.8% 22.2% .644 0.85 (0.42-1.71)ACUTE CORONARY SYNDROME AND
ACUTE MYOCARDIAL INFARCTION
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BACKGROUND Current guidelines deem percutaneous coronary
intervention (PCI) of a non-infarct related artery (n-IRA) at the time of
primary PCI (pPCI). This approach is being challenged by recent
studies, which show beneﬁts of complete rather than culprit vessel-
only revascularization at the time of pPCI. However, these studies
assessed grade of stenosis in the n-IRA by visual estimate. The impact
of fractional-ﬂow reserve (FFR) measurements during pPCI of n-IRA
has not been assessed.
METHODS COMPARE ACUTE is an ongoing prospective, randomized
strategy trial carried out at 22 sites across Europe and Asia. Patients
are randomly allocated (2:1) to receive either FFR guided multi-vessel
(MV) PCI vs. culprit vessel-only PCI with blinded FFR measurements
of n-IRA lesions in the setting of STEMI. The primary study endpoint
is MACCE deﬁned as death, myocardial infarction, any revasculari-
zation, or cerebral accident at 12 months. FFR measurements were
done directly after completion of pPCI in all n-IRA with visual esti-
mate of 50% stenosis. Positive FFR measurement was deﬁned
as 0.80 under maximal hyperemia.
RESULTS From July 2011 to April 2015, 728 STEMI patients undergo-
ing primary PCI with multi-vessel disease were enrolled. Mean age
was 62.0  10.4 (77.1% male) with Killip class I at presentation in
95.3%. In 37.3% the pPCI was performed in the LAD, 44.0% in the RCA
and 18.7% in the RCX. Successful pPCI deﬁned as TIMI 3 ﬂow was
achieved in 95.8%. FFR-measurements of 1000 n-IRA vessels (1023
lesions) were performed in the LAD in 40.1%, RCA 25.8% and RCX
34.1%. In 54% the FFR measurement of a n-IRA lesion was negative
and in 40% positive, 6% had no data available yet. On patient level
57% of the STEMI patients with angiographic multi-vessel disease had
no hemodynamic signiﬁcant lesions in the n-IRA.
CONCLUSIONS This preliminary data from the COMPARE ACUTE trial
indicates that a high portion of lesions found in non-infarct related
arteries with visual estimated stenosis of >50% are FFR negative. This
aspect should be taken into account during the debate on multi-vessel
primary PCI in STEMI patients.
CATEGORIES CORONARY: Acute Myocardial Infarction
KEYWORDS Fractional ﬂow reserve, Multivessel disease, ST elevation
myocardial infarctionTCT-2
Early or late intervention in patients with transient ST-segment elevation
acute coronary syndromes: subgroup analysis of the ELISA-3 trial
Erik A. Badings,1 Wouter Remkes,2 Salem H. The,3
Jan-Henk E. Dambrink,2 Jan Van Wijngaarden,1 Geert Tjeerdsma,4
Saman Rasoul,5 Jorik Timmer,2 Marloes Van Der Wielen,6 Dirk J. Lok,1
Rik Hermanides,2 Arnoud van ’t Hof2
1Deventer Ziekenhuis, Deventer, Netherlands; 2Isala Klinieken, Zwolle,
Netherlands; 3Treant Zorggroep, locatie Ziekenhuis Bethesda,
Hoogeveen, Netherlands; 4Ziekenhuis De Tjongerschans, Heerenveen,
Netherlands; 5Atrium Medisch Centrum, Heerlen, Netherlands; 6Treant
Zorggroep, locatie Ziekenhuis Bethesda, Hoogeveen, Netherlands
BACKGROUND Current guidelines recommend immediate revascu-
larization in patients with ST-segment elevation acute coronary
syndrome (STE-ACS). However, to date no evidence exists for
optimal treatment of ACS patients with initial ST elevation but
normalization of ST-segment elevation and anginal symptoms
before revascularization (transient ST-segment elevation or T-STE
ACS). We performed a pre-deﬁned subgroup analysis of the ELISA-3
trial to evaluate incidence and characteristics of patients with
T-STE ACS and to compare outcome of an early to a late invasive
strategy.
METHODS The ELISA-3 study is a prospective, multicentre trial in
which 542 patients hospitalized with high risk NSTE-ACS were ran-
domized to either an early (angiography and revascularization if
appropriate < 12h) or late invasive strategy (>48 h after randomiza-
tion). All patients were treated according to the guidelines. Incidence
and characteristics of patients with T-STE ACS were investigated and
effect of an early to a late invasive strategy in terms of combined
incidence of death, reinfarction and/or recurrent ischemia after 30
days and 2 years follow-up was compared.
RESULTS Transient ST elevation was seen in 129 (24.2%) patients
before randomization. In patients with T-STE, mean age was lower
(67.6 vs 71.4 y) and GRACE RISK score higher (142 vs 134). Incidence of
the composite endpoint after 30 days did not differ signiﬁcantly, but
was lower after 2 years follow-up in patients with T-STE ACS (20.3 vs
32.0%, p¼0.013), mainly driven by lower mortality (1.6 vs 9.5%
p¼0.004). No signiﬁcant interaction was found between T-STE and
treatment strategy on outcome. Within the group of patients with T-
STE ACS, early treatment showed a trend towards a lower incidence of
the combined endpoint after 30 days (5.8 vs 12.7%) and 2 years (18.8 vs
22.2%) follow up but these differences were not statistically signiﬁ-
cant (table 1). Enzymatic Infarct Size as assessed by a single cardiac
Troponin T, measured at 72-96 hours after admission or at discharge
was comparable.ischemia
death 1.6% 2.9% 0% .503 NA
MI 4.1% 4.3% 3.7% 1.00 1.17 (0.20-6.78)
recurrent ischemia 16.3% 14.5% 18.5% .548 0.78 (0.35-1.74)
PEP¼Primary End Point; IQR ¼ Inter Quartile Range
B2 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5CONCLUSIONS In this population of high risk NSTE-ACS patients,
transient ST elevation was present in 24% of patients. Clinical
outcome at long term follow-up was better as compared to patients
without T-STE. An early invasive strategy in patients with T-STE ACS
was feasible but not superior to a late invasive strategy in terms of the
combined primary endpoint of death, reinfarction and/or recurrent
ischemia. Infarct size was comparable. Postponement of intervention
for prolonged pharmacological pretreatment did not result in
improved outcome. Prospective, randomized trials are necessary for
more evidence in the optimal treatment of these patients. ISRCTN
register 39230163
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BACKGROUND The Thrombus Aspiration in ST-Elevation myocardial
infarction in Scandinavia (TASTE) trial did not demonstrate clinical
beneﬁt of thrombus aspiration (TA). High risk patients might beneﬁt
from TA.
METHODS The TASTE trial was a multicenter, randomized,
controlled, open-label trial obtaining endpoints from national regis-
tries. Patients (n¼7244) with ST segment elevation myocardial
infarction (STEMI) undergoing percutaneous coronary intervention
(PCI) were randomly assigned 1:1 to TA and PCI or to PCI alone. We
assessed the one-year clinical effect of TA in a sub-group with
potentially large anterior STEMI: mid or proximal left anterior
descending coronary artery infarct lesion, TIMI 0-2 ﬂow, and symp-
tom-onset-to-PCI time 5 h. In this sub-study, patient eligibility
criteria corresponded to that of the Intracoronary Abciximab and
Aspiration Thrombectomy in Patients with Large Anterior Myocardial
Infarction (INFUSE-AMI) study.
RESULTS In total, 1826 patients fulﬁlled inclusion criteria. All-cause
mortality at one year of patients randomized to TA did not differ from
those randomized to PCI only [hazard ratio (HR) 1.05, 95% conﬁdence
interval (CI) 0.74-1.49, P¼0.77]. Rates of rehospitalization for
myocardial infarction (MI), heart failure (HF), and stent thrombosis
(ST) did not differ between groups (HR 0.87, 95% CI 0.51-1.46, P¼0.59;
HR 1.10 95% CI 0.77-1.58, P¼0.58; and HR 0.75, 95% CI 0.30-1.86,
P¼0.53; respectively). This was also the case for the combined
endpoint of all-cause mortality, and rehospitalization for MI, HF, or ST
(HR 1.00, 95% CI 0.79-1.26, P¼0.99).CONCLUSIONS In patients with STEMI and large area of myocardium
at risk, TA did not affect outcome within one year.
CATEGORIES CORONARY: Thrombus / Thrombectomy and Embolic
Protection
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BACKGROUND Spontaneous coronary artery dissection (SCAD) is an
infrequent but important cause of myocardial infarction (MI) in
women. Chronic exposure to hormonal therapy, ﬂuctuation in hor-
monal levels, and a history of multiple pregnancies had been postu-
lated to predispose to SCAD. However, these were not well described
in the literature.
METHODS Women with SCAD who have consented and are prospec-
tively followed in our Vancouver General Hospital SCAD registries are
included in this study. Their background hormonal exposure, preg-
nancy, and gynecological histories were extracted from question-
naires, clinical histories, and medical records. These were correlated
to in-hospital and long-term outcomes.
RESULTS We included 187 women with SCAD, with mean age 52.6 
8.7 years. The majority were Caucasian (83.4%) and 74.0% had
ﬁbromuscular dysplasia. All patients presented with MI. Mean num-
ber of pregnancy in this cohort was 2.5, with 45 (24.1%) and 25 (13.4%)
having 4 and 5 pregnancies, respectively. Mean number of live
births (parity) was 1.8, with 52 (27.8%) having 3 births, and 16 (8.6%)
having 4 births. There were 3 post-partum SCAD (<1 year) and they
were still breastfeeding. In terms of hormonal therapy, 28 (15.0%)
were actively on hormonal therapy; 5 (2.7%) had prior fertility treat-
ment, 51 (27.3%) had hormone replacement therapy (HRT), 76 (40.6%)
had oral contraception, and 36 (19.3%) had gynecological procedures.
There were 107 (57.2%) post-menopausal women, and 23 (12.3%) were
peri-menopausal at presentation. There was no death during acute
SCAD admission, but 3 died at follow-up (mean 4.1  3.9 years), and 36
(19.3%) had recurrent SCAD. Patients actively on hormones had higher
rate of recurrent SCAD (32.1% vs. 15.8%, p¼0.039). There was a higher
recurrent MI rate in premenopausal women during index admission
(8.9% vs. 1.9%, p¼0.037). There was no signiﬁcant difference in in-
hospital and follow-up events in women with past hormonal therapy,
post-partum women, or those with parity 4 or gravida 5.
CONCLUSIONS Signiﬁcant proportion of women with SCAD had
exposure to hormonal therapy or had multiple pregnancies/births.
Patients actively on hormonal therapy appeared to have higher
recurrent SCAD events at follow-up.
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BACKGROUND Percutaneous closure of ventricular septal rupture
(VSR) complicating acute myocardial infarction appears to be safe and
effective treatment, but there is no uniﬁed opinion about the inter-
vention timing for transcatheter closure due to the lack of large-scale
prospective clinical research.
METHODS Between October 2010 and April 2013, 43 consecutive ST-
elevation myocardial infarction (STEMI) complicating VSR patients
who had indications of primary transcatheter closure were enrolled in
our study. We excluded cardiogenic shock patients. These patients
were randomly assigned to either the early intervention group (n¼21)
or the late intervention group (n¼22). We applied percutaneous
closure of VSR within 2 weeks after STEMI for patients in early
intervention group, while we applied percutaneous closure of VSR in
6 weeks after STEMI for patients in late intervention group. We
recorded the procedure-related complications and followed up these
patients for 2 years.
